Table 1

Patient characteristics at initiation of HAART stratified by gender (n = 908)
Women Men
    p-value
    1
Subjects, n(%) 473 (52.1) 435 (47.9) -
Follow-up from initiation of HAART (years), median (IQR) 5.9 (3.2-8.7) 5.7 (2.7-8.5) -
Follow-up time from initiation of HAART, (person-years) 2833 2519
Age in years at HAART initiation, median (IQR) 33.0 (28.6-40.1) 43.2 (35.3-51.7) <0.0001
Race, n(%)
 White 137 (29.0) 319 (73.7) <0.0001
 Asian 76 (16.1) 12 (2.8)
 Black 250 (53.0) 90 (20.8)
 Other 9 (1.9) 12 (2.8)
 (missing) (1) (2)
Place of HIV transmission, n(%)
 Denmark 127 (28.5) 150 (38.3) <0.0001
 Europe + US 19 (4.3) 29 (7.4)
 Africa 224 (50.3) 140 (35.7)
 Asia 72 (16.2) 63 (16.1)
 Other 3 (0.7) 10 (2.6)
 (missing) (28) (43)
CD4 cell count at HAART initiation (cells/μl), median (IQR)
All women included 196 (90–290) 180 (63–290) 0.12 (0.026)
Pregnant women excluded 170 (80–270) 180 (63–290) 0,87 (0,21)
HIV-RNA at HAART initiation (copies/mL), median (IQR) All women included 50,800 (12,500-204,000) 126,155 (32,200-501,000) <0.0001 (0.0003)
Pregnant women excluded 61,320 (16,519-237,000) 126,155 (32,200-501,000) <0.0001 (0.0066)
Acute HIV infection at HAART initiation, n(%) 4 (0.9) 15 (3.5) 0.0089
AIDS before HAART initiation, n(%) All women included 88 (18.6) 106 (24.4) 0.034
n(%) of all patients except pregnant women Pregnant women excluded 87 (21.8) 106 (24.4) 0.37
Pregnant at HAART initiation, n(%) 59 (12.5) - -
Antiretroviral therapy before HAART, n(%) 14 (3.0) 12 (2.8) 0.86
Hepatitis B co-infection2, n(%) 30 (6.3) 20 (4.6) 0.25
Hepatitis C co-infection3, n(%) 0 (0) - -
First-line HAART 01.01.1997 – 31.12.2002 All women included
 3 NRTI’s4 21 (9.5) 9 (4.3) 0.29
 2 NRTI’s + efavirenz 71 (32.0) 76 (35.9)
 2 NRTI’s + nevirapine 7 (3.2) 6 (2.8)
 2 NRTI’s + PI’s5 93 (41.9) 94 (44.3)
 Other regimen 30 (13.5) 27 (12.7)
Pregnant women excluded
 3 NRTI’s 21 (11.1) 9 (4.7) 0.13
 2 NRTI’s + efavirenz 66 (37.7) 76 (39.8)
2 NRTI’s + nevirapine 5 (2.6) 6 (3.1)
 2 NRTI’s + PI’s 73 (38.4) 94 (44.3)
 Other regimen 25 (13.2) 27 (12.7)
First-line HAART 01.01.2003 – 31.12.2009 All women included
 3 NRTI’s 3 (1.2) 1 (0.5) <0.0001
 2 NRTI’s + efavirenz 150 (59.8) 179 (80.3)
 2 NRTI’s + nevirapine 17 (6.8) 13 (5.8)
 2 NRTI’s + PI’s 73 (29.1) 20 (9.0)
 Other regimen 8 (3.2) 10 (4.5)
Pregnant women excluded
 3 NRTI’s 3 (1.4) 1 (0.5) 0.066
 2 NRTI’s + efavirenz 148 (70.5) 179 (80.3)
 2 NRTI’s + nevirapine 15 (7.1) 13 (5.8)
 2 NRTI’s + PI’s 36 (17.1) 20 (9.0)
 Other regimen 8 (3.8) 10 (4.5)

Figures are number (%) or median (interquartile range - IQR).

1P-values were calculated using chi-square or Fisher’s exact test (when appropriate) for categorical variables and Kruskal-Wallis test for continuous variables. CD4 cell counts and viral loads were subsequently analysed by linear regression adjusting for age and race (p-value in parenthesis). 2 Patients with positive Hbs-Ag in the study period, 3 Hepatitis C was an exclusion criteria, 4 Nucleoside reverse transcriptase inhibitors (NRTI), 5 Protease Inhibitors (PI’s).

Thorsteinsson et al.

Thorsteinsson et al. BMC Infectious Diseases 2012 12:293   doi:10.1186/1471-2334-12-293

Open Data